Insider Sales at Bolt Biotherapeutics Show Confidence, Not a Sell‑Off
Insights from Bolt Biotherapeutics’ latest insider sales: executive moves are tax‑driven, leadership still holds big stakes and remains bullish on its oncology pipeline.
4 minutes to read